Bio-Techne（TECH）株式概要バイオテクネ・コーポレーションは、その子会社とともに、研究、診断、バイオプロセス市場向けのライフサイエンス試薬、機器、サービスを世界中で開発、製造、販売している。 詳細TECH ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長1/6過去の実績4/6財務の健全性6/6配当金0/6報酬収益は年間15%増加すると予測されています 過去1年間で収益は147.9%増加しました リスク分析リスクチェックの結果、TECH 、リスクは検出されなかった。すべてのリスクチェックを見るTECH Community Fair Values Create NarrativeSee what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.Analyst Price TargetsAN3.7% overvaluedAnalystConsensusTarget•10d agoTECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools19707AN28.0% overvaluedAnalystLowTarget•24d agoUS Funding Uncertainty Will Squeeze Life Sciences Yet Spark Resilience3402AN0.9% undervaluedAnalystHighTarget•1mo agoRising Healthcare Spending And Aging Population Will Expand Biotech Markets3100Top Analyst NarrativesAN3.7% overvaluedAnalystConsensusTarget•10d agoTECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools19707AN28.0% overvaluedAnalystLowTarget•24d agoUS Funding Uncertainty Will Squeeze Life Sciences Yet Spark Resilience3402AN0.9% undervaluedAnalystHighTarget•1mo agoRising Healthcare Spending And Aging Population Will Expand Biotech Markets3100View all narrativesBio-Techne Corporation 競合他社QiagenSymbol: NYSE:QGENMarket cap: US$9.1bRevvitySymbol: NYSE:RVTYMarket cap: US$13.9bBio-Rad LaboratoriesSymbol: NYSE:BIOMarket cap: US$10.1bStevanato GroupSymbol: NYSE:STVNMarket cap: US$6.2b価格と性能株価の高値、安値、推移の概要Bio-Techne過去の株価現在の株価US$72.3252週高値US$72.6252週安値US$43.20ベータ1.281ヶ月の変化1.01%3ヶ月変化50.01%1年変化26.68%3年間の変化-9.78%5年間の変化-41.56%IPOからの変化11,188.98%最新ニュースRecent Insider Transactions Derivative • Aug 19CEO, President & Director exercised options and sold US$783k worth of stockOn the 15th of August, Kim Kelderman exercised options to acquire 11k shares at no cost and sold these for an average price of US$72.40 per share. This trade did not impact their existing holding. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.Declared Dividend • Aug 14Fourth quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 17th August 2026 Payment date: 28th August 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 27%. Cash payout ratio: 19%.お知らせ • Aug 13Bio-Techne Corporation Announces Cash Dividend on Common Shares for the Quarter Ended June 30, 2026, Payable on August 28, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Reported Earnings • Aug 13Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: US$1.17 (up from US$0.47 in FY 2025). Revenue: US$1.22b (flat on FY 2025). Net income: US$181.9m (up 148% from FY 2025). Profit margin: 15% (up from 6.0% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.5%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.ナラティブ更新 • Aug 12TECH: Acquisition Offer And Resilient Pharma Demand Will Support A Balanced OutlookAnalysts have lifted their price target for Bio-Techne from about $61 to roughly $70, citing updated assumptions for revenue growth, profit margins and future P/E. These changes shift their fair value framework higher in spite of a slightly different discount rate outlook.Recent Insider Transactions Derivative • Jul 31CEO, President & Director exercised options and sold US$702k worth of stockOn the 28th of July, Kim Kelderman exercised 35.00k options at around US$47.60, then sold 29k of the shares acquired at an average of US$72.07 per share and kept the remainder. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$8.9m more than they bought, via options and on-market transactions in the last 12 months.最新情報をもっと見るRecent updatesRecent Insider Transactions Derivative • Aug 19CEO, President & Director exercised options and sold US$783k worth of stockOn the 15th of August, Kim Kelderman exercised options to acquire 11k shares at no cost and sold these for an average price of US$72.40 per share. This trade did not impact their existing holding. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.Declared Dividend • Aug 14Fourth quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 17th August 2026 Payment date: 28th August 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 27%. Cash payout ratio: 19%.お知らせ • Aug 13Bio-Techne Corporation Announces Cash Dividend on Common Shares for the Quarter Ended June 30, 2026, Payable on August 28, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.Reported Earnings • Aug 13Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: US$1.17 (up from US$0.47 in FY 2025). Revenue: US$1.22b (flat on FY 2025). Net income: US$181.9m (up 148% from FY 2025). Profit margin: 15% (up from 6.0% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.5%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.ナラティブ更新 • Aug 12TECH: Acquisition Offer And Resilient Pharma Demand Will Support A Balanced OutlookAnalysts have lifted their price target for Bio-Techne from about $61 to roughly $70, citing updated assumptions for revenue growth, profit margins and future P/E. These changes shift their fair value framework higher in spite of a slightly different discount rate outlook.Recent Insider Transactions Derivative • Jul 31CEO, President & Director exercised options and sold US$702k worth of stockOn the 28th of July, Kim Kelderman exercised 35.00k options at around US$47.60, then sold 29k of the shares acquired at an average of US$72.07 per share and kept the remainder. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$8.9m more than they bought, via options and on-market transactions in the last 12 months.ナラティブ更新 • Jul 29TECH: Merger Premium And Deal Uncertainty Will Restrain Future Earnings AppealAnalysts have nudged their price target for Bio-Techne higher to reflect a shift in fair value from $55.05 to $56.51. This change is supported by updated assumptions for revenue growth, profit margins and future P/E levels, as well as a slightly lower discount rate.ナラティブ更新 • Jul 15TECH: AI Protein Expansion And Portfolio Rebrand Will Support Balanced Long-Term UpsideAnalysts have reduced their price target on Bio-Techne to $73 from $75, reflecting updated assumptions about the balance between revenue growth expectations, lower projected profit margins, and a slightly higher future P/E multiple. What’s in the News for Bio-Techne Bio-Techne and Merck KGaA agreed to a definitive acquisition deal in which Merck KGaA plans to acquire Bio-Techne for US$73 per share in cash, valuing the company at about US$11.5b and implying an enterprise value of roughly US$11.3b, with the transaction subject to regulatory and shareholder approvals and customary closing conditions.お知らせ • Jul 08Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein PortfolioBio-Techne Corporation announced the launch of new additions to its R&D Systems AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing. The newly launched proteins include: FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success.ナラティブ更新 • Jul 01TECH: Pending Merger Premium Will Constrain Future Earnings AppealBio-Techne's updated analyst price target has been trimmed from about $56.78 to $55.05, as analysts factor in slightly higher assumed revenue growth and P/E levels, along with modestly lower profit margin estimates. What’s in the News for Bio-Techne Merck KGaA agreed to acquire Bio-Techne in an all cash transaction valued between US$11.3b and US$11.5b, which Merck states represents about a 36% premium to Bio-Techne’s trading price at announcement.ライブニュース • Jun 27Merck KGaA Announces $11.3 Billion Bio-Techne Acquisition Targeting Early 2027 CompletionMerck KGaA has agreed to acquire Bio-Techne in an all-cash transaction valued between $11.3 billion and $11.5 billion, a deal that carries a roughly 36% premium to Bio-Techne’s recent trading price and has been unanimously approved by Bio-Techne’s board, pending regulatory approvals and a shareholder vote. The acquisition is intended to fold Bio-Techne’s protein detection instruments and spatial biology diagnostic technologies into Merck’s broader life science portfolio, with both companies expecting operational synergies and an accretive effect on Merck’s earnings after completion, which is currently targeted for early 2027. Bio-Techne’s share price is around $71.00, with the stock up 47.6% over the past 30 days, reflecting a sharp re-rating ahead of the proposed buyout. The key question for shareholders is how the final transaction terms, timing and regulatory conditions compare with the current market price and whether any deal uncertainty or timeline slippage could affect the risk and return trade-off.お知らせ • Jun 27Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion.Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion on June 25, 2026. Merck KGaA will acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion (€9.9 billion). The planned acquisition will be funded through a combination of existing cash on hand and proceeds from new debt. The transaction is subject to approval of merger agreement by target board, approval by regulatory board / committee and approval of offer by target shareholders, subject to satisfaction of customary closing conditions. The proposed transaction has been approved by Bio-Techne's Board of Directors. The transaction is expected to close by late 2026 or early 2027. The proposed transaction is expected to be immediately accretive to EBITDA pre margin of both Life Science and the Group post-closing and EPS pre accretive by year 3 after closing. Cost synergies of approximately $159.6 million (€140 million) are expected to be fully realized by year 3 after closing. Guggenheim Securities, LLC acted as financial advisor for Merck KGaA. J.P. Morgan Securities, Inc. acted as financial advisor for Merck KGaA. Sullivan & Cromwell LLP acted as legal advisor to Merck KGaA. Goldman Sachs & Co. LLC acted as financial advisor for Bio-Techne Corporation. Sidley Austin LLP acted as legal advisor for Bio-Techne Corporation.Price Target Changed • Jun 26Price target increased by 10% to US$67.69Up from US$61.31, the current price target is an average from 13 analysts. New target price is approximately in line with last closing price of US$71.00. The company is forecast to post earnings per share of US$1.17 for next year compared to US$0.47 last year.Buy Or Sell Opportunity • Jun 25Now 39% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to US$70.67. The fair value is estimated to be US$50.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has declined by 43%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.分析記事 • Jun 18Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn CollaborationBio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits...ナラティブ更新 • Jun 17TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin UpsideAnalysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.ライブニュース • Jun 16Bio-Techne Shares Rise 4% as Activist Investor Urges Review of Company OptionsBio-Techne shares moved higher after Ananym Capital Management disclosed a significant stake in the company. The activist investor is urging Bio-Techne to conduct a broad review of its options, including a possible sale. Ananym argues that exploring a transaction could provide more value to shareholders than the company remaining independent. An activist campaign of this type often puts management under pressure to examine portfolio priorities, capital allocation and potential interest from buyers. This can lead to changes in how Bio-Techne is run or structured. Investors may want to watch for any response from Bio-Techne’s board, including whether it forms a special committee, sets out a formal review process or rejects the call, as each path can carry different execution risks and timelines.ライブニュース • Jun 06Bio-Techne Unveils Integrated Four-Hour Workflow for Faster Bispecific and Biosimilar AnalysisBio-Techne and Refeyn announced a combined workflow that links charge and size characterization for bispecific antibodies and biosimilars. The workflow connects Bio-Techne’s icIEF fractionation system with Refeyn’s mass photometry platform to correlate charge heterogeneity with molecular weight and aggregation at single-molecule resolution. The integrated process is designed to run in roughly four hours and is aimed at reducing development risk and speeding up biosimilar manufacturing. This collaboration points to a push by Bio-Techne to position its analytical tools more deeply in complex biologics workflows, especially where bispecifics and biosimilars require tighter quality characterization. For investors, the key question is how widely this four-hour workflow will be adopted by biopharma customers and whether it can translate into higher demand for Bio-Techne’s analytical systems and related consumables, given the growing focus on efficiency and risk reduction in biologics development.ナラティブ更新 • Jun 03TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward OutlookAnalysts have lowered their price target on Bio-Techne from $75.25 to $61.42, citing updated assumptions that include slightly lower revenue growth, modestly higher profit margins, and a reduced future P/E multiple. What's in the News Bio-Techne stock rallied about 12% over a recent five day period, adding roughly US$780 million in market value to reach around US$7.5b in market capitalization, according to recent coverage.ナラティブ更新 • May 12TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future UpsideAnalysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).Recent Insider Transactions Derivative • May 11Executive VP of Finance & CFO exercised options and sold US$517k worth of stockOn the 5th of May, James Hippel exercised 62.00k options at around US$47.60, then sold 57k of the shares acquired at an average of US$9.08 per share and kept the remainder. Since September 2025, James' direct individual holding has increased from 129.88k shares to 153.67k. Company insiders have collectively sold US$9.9m more than they bought, via options and on-market transactions in the last 12 months.Declared Dividend • May 11Third quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 18th May 2026 Payment date: 29th May 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 46%. Cash payout ratio: 19%.Price Target Changed • May 07Price target decreased by 11% to US$64.55Down from US$72.27, the current price target is an average from 11 analysts. New target price is 27% above last closing price of US$50.91. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.20 for next year compared to US$0.47 last year.お知らせ • May 07Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026.Reported Earnings • May 06Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: EPS: US$0.33 (up from US$0.14 in 3Q 2025). Revenue: US$311.4m (down 1.5% from 3Q 2025). Net income: US$51.0m (up 126% from 3Q 2025). Profit margin: 16% (up from 7.1% in 3Q 2025). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Recent Insider Transactions Derivative • Apr 26Executive VP of Finance & CFO exercised options and sold US$3.3m worth of stockOn the 22nd of April, James Hippel exercised options to acquire 56k shares at no cost and sold these for an average price of US$58.58 per share. This trade did not impact their existing holding. Since September 2025, James' direct individual holding has increased from 129.88k shares to 142.72k. Company insiders have collectively sold US$9.2m more than they bought, via options and on-market transactions in the last 12 months.Buy Or Sell Opportunity • Apr 23Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to US$52.20. The fair value is estimated to be US$71.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Earnings per share has declined by 42%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.ナラティブ更新 • Apr 20TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings PotentialAnalysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.Recent Insider Transactions Derivative • Apr 19CEO, President & Director exercised options and sold US$1.9m worth of stockOn the 14th of April, Kim Kelderman exercised options to acquire 32k shares at no cost and sold these for an average price of US$58.66 per share. This trade did not impact their existing holding. For the year to June 2019, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Kim's direct individual holding has increased from 50.97k shares to 53.08k. Company insiders have collectively sold US$5.9m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Apr 18Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio BrandsBio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls.ナラティブ更新 • Apr 05TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings MultipleAnalysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).お知らせ • Mar 25Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification KitsBio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample.ナラティブ更新 • Mar 22TECH: Clinical Platform Adoption Will Support Higher Future Earnings MultipleAnalysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).ナラティブ更新 • Mar 06TECH: Multiomic Platform Expansion Will Support Higher Future Earnings MultipleAnalysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).Buy Or Sell Opportunity • Feb 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.5% to US$57.52. The fair value is estimated to be US$72.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Earnings per share has declined by 42%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 24% per annum over the same time period.ナラティブ更新 • Feb 20TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward OutlookNarrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.お知らせ • Feb 16Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical LaboratoriesBio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex™? assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.分析記事 • Feb 12There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) EarningsShareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...お知らせ • Feb 11Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026Bio-Techne Corporation announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University.Price Target Changed • Feb 09Price target increased by 7.5% to US$75.25Up from US$70.00, the current price target is an average from 12 analysts. New target price is 13% above last closing price of US$66.78. Stock is down 4.5% over the past year. The company is forecast to post earnings per share of US$1.26 for next year compared to US$0.47 last year.Declared Dividend • Feb 06Second quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 13th February 2026 Payment date: 27th February 2026 Dividend yield will be 0.5%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 31%. Cash payout ratio: 22%.Reported Earnings • Feb 05Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: EPS: US$0.24 (up from US$0.22 in 2Q 2025). Revenue: US$295.9m (flat on 2Q 2025). Net income: US$38.0m (up 8.9% from 2Q 2025). Profit margin: 13% (up from 12% in 2Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.ナラティブ更新 • Feb 05TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings MultipleAnalysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).お知らせ • Feb 04Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026.お知らせ • Feb 03Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with A Fully Defined Synthetic AlternativeBio-Techne Corporation announced the launch of Cultrex™? Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices. Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture. Cultrex Synthetic Hydogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic HydrogEL launch represents an important step toward the broader adoption of organoid models in support of translational and regulatory- aligned research. Its controlled composition supports consistency and traceability as programs advance toward regulatory-facing studies. This launch further expands Bio-Techne's robust portfolio of solutions for stem cell and organoid culture, including Cultrex Basement Membrane Extracts (BME), as well as recombinant cytokines and growth factors, AI-modified proteins, small molecules, media, and supplements. Together, these offerings provide researchers with the flexibility to select ECM solutions aligned with their experimental, scalability, and regulatory needs.お知らせ • Jan 28Bio-Techne Launches Simple Plex Ultra- Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological BiomarkersBio-Techne Corporation announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible biofluids such as blood. The new, ultrasensitive assays overcome this barrier by delivering step-change improvements on the Ella platform in analytical sensitivity and reliable quantification of key biomarkers, including NFL, GFAP, pTau 217, and Amyloid b (aa1-42). This capability enables researchers to detect subtle, early biological changes that are often missed, accelerating insights into disease onset, progression, and treatment response. The assays build on Ella's proven performance, which is cited in more than 200 peer-reviewed neurology-focused publications and widely adopted in translational and clinical research, driving breakthrough diagnostic and therapeutic advances. Ella's automated workflow reduces manual steps and variability, delivering ultrasensitive assay results with an overall runtime of under three hours. These assays are intended for Research Use Only. This launch strengthens Bio-Techne's immunoassay leadership by combining ultrasensitive proteomic assays with automated instrumentation that improves reproducibility, throughput, and data quality. The Ella platform has been cited in more than 1,000 peer-reviewed publications. Bio-Techne's broad proteomic and spatial biology portfolio continues to drive breakthroughs in neuroscience research and advance precision medicine.ナラティブ更新 • Jan 22TECH: Multiomic Automation And Buybacks Will Support A Steady Forward OutlookNarrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking Alphaナラティブ更新 • Jan 08TECH: Multiomic Partnerships And Automation Will Support A Steady Forward OutlookAnalysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).ナラティブ更新 • Dec 16TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future OutlookAnalysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).お知らせ • Dec 09Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein AnalysisBio-Techne Corporation announced the expanded launch and first shipment of its next-generation Leo System, powered by Simple Western Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours.ナラティブ更新 • Dec 01TECH: Share Buyback Completion And New Partnerships Will Maintain Steady OutlookAnalysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.ナラティブ更新 • Nov 17TECH: Share Buyback Momentum Will Drive Stronger Performance AheadNarrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).分析記事 • Nov 08Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkBio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...Declared Dividend • Nov 07First quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 17th November 2025 Payment date: 28th November 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 64%. Cash payout ratio: 22%.Reported Earnings • Nov 06First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: EPS: US$0.25 (up from US$0.21 in 1Q 2025). Revenue: US$286.6m (down 1.0% from 1Q 2025). Net income: US$38.2m (up 14% from 1Q 2025). Profit margin: 13% (up from 12% in 1Q 2025). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.お知らせ • Nov 05Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.お知らせ • Nov 04Bio-Techne Corporation and Nucleai Announces the Presentation of Pivotal Data from the SECOMBIT Clinical Trial at the Society for Immunotherapy of Cancer 2025 Annual MeetingBio-Techne Corporation and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis. Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai's multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB). Key Findings: Arm A (MAPKi - ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes. Arm B (ICB - MAPKi): PD-1+ CD8 T- cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival. Arm C (MAPKi - IC B - MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis. The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment. Availability at SITC 2025 Bio-Techne's full spatial biology portfolio--including the new ProximityScope™? assay and the extended SPYRE™? portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators.ナラティブ更新 • Nov 03TECH: Product Advances And Index Changes Will Influence Future Demand For Precision ToolsAnalysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.お知らせ • Oct 28Bio-Techne Launches ProximityScope Assay on the Bond Rx Platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions ResearchBio-Techne Corporation announced the launch of the ProximityScope™ assay, a spatial solution developed for seamless integration with the BOND RX staining platform from Leica Biosystems. This powerful combination enables researchers to visualize functional protein-protein interactions on fixed tissue with subcellular resolution - bringing Leica's automation excellence from Leica Biosystems to the forefront of spatial biology. The ProximityScope assay provides a clear, visual signal only when two proteins of interest are physically close, revealing previously inaccessible insights into biological mechanisms. Designed to work in tandem with the BOND RX stained system from Leica Biosystems, the assay also integrates with ACD's RNAscope Multiomic LS kit, enabling enhanced detection of RNA and protein on the same tissue section. This offers scientists a uniquely powerful tool for both discovery and translational research, sparing precious tissue while delivering novel insights. Traditional methods for studying protein interactions, such as bulk pull-down assays or non-spatial proximity assays, lack localization data or require dissociation cells that lose their spatial orientation. ProximityScope addresses this gap by combining high sensitivity with high specificity and low background, providing unparalleled accuracy and confidence in results. Key applications include visualizing cell-cell interactions for studying immune checkpoints or bispecific antibodies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics for toxicity and target specificity, and investigating intracellular interactions involved in transcriptional activation.ナラティブ更新 • Oct 20Chronic Disease Trends And Precision Medicine Will Shape DemandNarrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.お知らせ • Oct 15Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025お知らせ • Sep 26Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical ApplicationsBio-Techne Corporation announced new advancements in its spatial biology portfolio for the RNAscope™? ISH technology and the Lunaphore COMET™?. These solutions help researchers and pathologists bridge the gap between translational research and clinical applications by enabling the detection of RNA and protein biomarkers on the same tissue section. RNAscope™? empowers pathologists and histologists to detect clinically relevant biomarkers--such as viral markers, secreted proteins, point mutations, and chromosomal translocations--within routine anatomic pathology workflows. COMET™? offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights. Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™? for assessing B-cell clonality with IGLL5 detection, and COMET™? for spatial profiling of lymphoid malignancies using a 21-plex seqIF™? panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability. Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26-30 in Long Beach, CA. Advanced Cell Diagnostics (ACD) and Lunaphore will exhibit at booths #139 and #427, respectively. Presentations include: RNAscope™? for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™? over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.) RNAscope™? of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™? for assess B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. seqIF™? Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™?) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Park's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.お知らせ • Sep 22+ 1 more updateBio-Techne Corporation, Annual General Meeting, Oct 30, 2025Bio-Techne Corporation, Annual General Meeting, Oct 30, 2025.ナラティブ更新 • Aug 27Chronic Disease Trends And Precision Medicine Will Shape DemandBio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Recent Insider Transactions Derivative • Aug 26Independent Director notifies of intention to sell stockRoeland Nusse intends to sell 17k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of August. If the sale is conducted around the recent share price of US$56.36, it would amount to US$960k. Since September 2024, Roeland's direct individual holding has increased from 43.10k shares to 44.56k. Company insiders have collectively sold US$3.0m more than they bought, via options and on-market transactions in the last 12 months.Declared Dividend • Aug 08Fourth quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 18th August 2025 Payment date: 29th August 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 38%. Cash payout ratio: 20%.Reported Earnings • Aug 06Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.お知らせ • Aug 06Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2025, Payable on August 29, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025.Recent Insider Transactions Derivative • Aug 01Executive VP of Finance & CFO exercised options and sold US$2.1m worth of stockOn the 29th of July, James Hippel exercised 168.62k options at around US$44.33, then sold 147k of the shares acquired at an average of US$58.55 per share and kept the remainder. Since September 2024, James' direct individual holding has increased from 99.93k shares to 106.61k. Company insiders have collectively sold US$4.7m more than they bought, via options and on-market transactions in the last 12 months.Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$58.78, the stock trades at a forward P/E ratio of 48x. Average trailing P/E is 40x in the Life Sciences industry in the US. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$61.27 per share.Major Estimate Revision • May 15Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$1.16 to US$1.01 per share. Revenue forecast steady at US$1.22b. Net income forecast to grow 70% next year vs 12% growth forecast for Life Sciences industry in the US. Consensus price target down from US$79.70 to US$70.11. Share price fell 3.1% to US$48.24 over the past week.お知らせ • May 12Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025Bio-Techne Corporation announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy 2025 meeting taking place in New Orleans between May 13th - 17th at the New Orleans Ernest N. Memorial Convention Center. Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo System will also be featured, with this instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run. Leading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics, a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond.Declared Dividend • May 11Third quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 19th May 2025 Payment date: 30th May 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 38%. Cash payout ratio: 23%.Price Target Changed • May 09Price target decreased by 11% to US$71.28Down from US$79.70, the current price target is an average from 12 analysts. New target price is 43% above last closing price of US$49.94. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$1.01 for next year compared to US$1.07 last year.New Risk • May 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin).Reported Earnings • May 07Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 57%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 17% per year.お知らせ • May 07+ 1 more updateBio-Techne Corporation (NasdaqGS:TECH) announces an Equity Buyback for $500 million worth of its shares.Bio-Techne Corporation (NasdaqGS:TECH) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its common. The repurchase program has no expiration date.お知らせ • Apr 24Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity DetectionBio-Techne Corporation announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes - offering a truly integrated spatial multiomic view. Conventional methods for studying molecular interactions in tissues that separately measure proteins and RNA risk losing spatial fidelity, while bulk proximity assays provide no localization data. Bio-Techne's proximity detection technology addresses these gaps with a clear visual signal at subcellular resolution, built to be compatible with the RNAscope Multiomic LS workflow on BOND RX. This capability is particularly valuable for research areas where context matters -- such as assessing immune checkpoint dynamics, investigating bispecific antibodies and studying protein interactions at synaptic junctions. The Early Access Program is available to select institutions and researchers interested in incorporating spatial protein proximity capabilities into their workflows. Proof-of-concept data and case studies will be shared at the 2025 American Association for Cancer Research annual meeting, presented by Bio-Techne's scientific team.お知らせ • Apr 15Bio-Techne Corporation to Report Q3, 2025 Results on May 07, 2025Bio-Techne Corporation announced that they will report Q3, 2025 results on May 07, 2025お知らせ • Mar 11Bio-Techne Corporation Begins Shipping Leo - A Next Generation High-Throughput Simple Western SystemBio-Techne Corporation announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization. Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.お知らせ • Mar 03Bio-Techne Launches New Panel Resolving Hard-To-Decipher Carrier Screening GenesBio-Techne Corporation announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX®? Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening research. This innovative kit helps laboratories resolve genes that are challenging to analyze by conventional short-read sequencing and only partially resolved by ancillary assays. The panel is available for research use only. In 2021, the American College of Medical Genetics and Genomics (ACMG) updated its recommendations for carrier screening to include many genes that cannot be analyzed by standard short-read sequencing. In fact, half of the 10 most common genes that contribute to the risk of couples having a child with a genetic disorder are problem for short-read sequencing. Until now, laboratories have relied on multiple test technologies, including MLPA, Sanger sequencing, qPCR, long-range PCR, and others, to analyze the recommended genes. The AmplideX Nanopore Carrier Plus Kit addresses two problems for laboratories: it provides a single streamlined method, and it delivers comprehensive sequencing data compared to alternative assays. By combining novel AmplideX long-range PCR and nanopore long reads, it directly captures large genomic variants. The 11-gene panel includes the most prevalent recommended genes that cannot be detected accurately with legacy short-read sequencing methods, allowing labs to replace a patchwork testing approach with a single workflow to simplify sample-to-answer results. The kit also includes software to enable straightforward analysis without the need for advanced bioinformatics resources.Seeking Alpha • Feb 27Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A BargainSummary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alphaお知らせ • Feb 20Bio-Techne Corporation Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial BiologyBio-Techne Corporation announced the launch of an expanded menu of human and mouse RNAscope™? in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species. Representing the most referenced spatial biology technology in the industry, RNAscope provides an unprecedented single-cell view of disease pathology and therapeutic response across a wide range of diseases. Backed by the RNAscope probe guarantee, this new addition to the large and growing RNAscope probe menu enables customers to easily accelerate validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available for purchase on bio-techne.com, customers can easily select RNAscope probes together with R&D Systems antibodies to further illuminate changes in cell phenotypes and functional states. With ready-to-use manual and automated formats available for each RNAscope probe, including for use on the automated Lunaphore COMET™? system, researchers can seamlessly advance new RNA and multiomic biomarkers from late discovery to translational research or clinical assay development using the same RNAscope probe design.お知らせ • Feb 18Bio-Techne Corporation Announces Release of GMP TcBuster Non-Viral Genome Engineering SystemBio-Techne Corporation announced the official release of GMP Transposase mRNA for the TcBuster™? non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene editing cell therapies, such as CAR-T or TCR generation. Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods for cell therapy development. The natural transposase has been enhanced through protein engineering, resulting in a hyperactive enzyme. As a result, multiple genes can be delivered from a GMP transposon simultaneously while maintaining high editing efficiency and a de-risked insertional profile. By negating the need for viral clearance methods, the TcBuster system also significantly reduces both the time to market and cost requirements for cell therapy developers. Moreover, Bio-Techne has a strong and reliable supply chain for both RUO & GMP grade reagents, including innovative options for closed-system manufacturing, making it a dependable option for scaling from research to clinical and commercial stages. The TcBuster system is compatible with a range of cell types, including immune cells and stem cells, and can be used for a wide range of applications, including autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and for engineering bioprocessing cell lines for therapeutic biologics production.Declared Dividend • Feb 07Second quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 14th February 2025 Payment date: 28th February 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 32%. Cash payout ratio: 20%.Reported Earnings • Feb 05Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.22 (up from US$0.17 in 2Q 2024). Revenue: US$297.0m (up 9.0% from 2Q 2024). Net income: US$34.9m (up 27% from 2Q 2024). Profit margin: 12% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 11% per year.お知らせ • Feb 05Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2024, Payable on February 28, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.お知らせ • Feb 04Bio-Techne Appoints Amy E. Herr to Board of DirectorsBio-Techne Corporation announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining the faculty at UC Berkeley in 2007, Dr. Herr has served in several university, national, and international leadership roles including as the Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub – an incubator for academic spin-out companies, and on the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB) for the National Institutes of Health, as well as governmental science advisory boards. Dr. Herr was a co-founder and advisory board member of Zephyrus Biosciences, which was acquired by Bio-Techne in 2016. Dr. Herr holds a Doctor of Philosophy in Mechanical Engineering from Stanford University and a Bachelor of Science in Engineering & Applied Science from Caltech. Dr. Herr's appointment completes a two-year process by the Board of Directors to identify and appoint successors to retiring directors Randy Steer, who retired in 2024, and Dr. Roeland Nusse, who will be retiring later in 2025. Dr. Herr will succeed Dr. Roeland Nusse.Recent Insider Transactions Derivative • Jan 28CEO, President & Director notifies of intention to sell stockKim Kelderman intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of January. If the sale is conducted around the recent share price of US$77.05, it would amount to US$1.0m. For the year to June 2018, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Kim's direct individual holding has decreased from 39.94k shares to 39.00k. Company insiders have collectively sold US$4.7m more than they bought, via options and on-market transactions in the last 12 months.お知らせ • Jan 11Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative MedicineBio-Techne announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO) and made under good manufacturing processes (GMP) for therapeutic development), as well as Wnt/RSPO1 Agonist, Wnt/RSPO2 Agonist, and Wnt/RSPO3 Agonist proteins. These innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. Leveraging generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design, Bio-Techne's expanded portfolio delivers next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability. The new products include: IL-2 Heat StableAgonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor-infiltrating lymphocytes (TIL) expansion. Activin A Hyperactive: Optimized for superior performance in regenerative medicine cell differentiation applications. FGF basic Heat Stable: A robust and versatile growth factor designed for improved protein stability and performance for stem cell culture applications, available in both RUO and GMP formats to support cell therapy manufacturing and advanced research. Wnt/RSPO 1, Wnt/RSPo2, and Wnt/R SPO3 Agonists: Key reagents for advancing stem cell research, organoid development, and regenerative medicine. With this expanded portfolio, Bio-Techne continues to lead the way in delivering disruptive innovations to the life sciences and therapeutic development communities. Bio-Techne designer proteins are available as part of market leading R&D Systems branded portfolio of proteins.株主還元TECHUS Life SciencesUS 市場7D-0.1%7.4%-1.5%1Y26.7%25.1%17.8%株主還元を見る業界別リターン: TECH過去 1 年間で25.1 % の収益を上げたUS Life Sciences業界を上回りました。リターン対市場: TECH過去 1 年間で17.8 % の収益を上げたUS市場を上回りました。価格変動Is TECH's price volatile compared to industry and market?TECH volatilityTECH Average Weekly Movement6.8%Life Sciences Industry Average Movement7.8%Market Average Movement7.2%10% most volatile stocks in US Market16.3%10% least volatile stocks in US Market3.1%安定した株価: TECH 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: TECHの 週次ボラティリティ ( 7% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19763,000Kim Keldermanwww.bio-techne.comバイオテクネ・コーポレーションは子会社とともに、研究、診断、バイオプロセス市場向けのライフサイエンス試薬、機器、サービスを開発、製造、販売している。同社は「タンパク質科学」、「診断と空間生物学」の2つのセグメントで事業を展開している。タンパク質科学部門では、サイトカインや成長因子、抗体、低分子化合物、組織培養血清、細胞選択技術など、ライフサイエンス研究、診断、細胞・遺伝子治療の様々な局面で使用される生物学的試薬を開発・製造している。この部門はまた、自動ウェスタンブロットや多重ELISAワークフロー用のプロテオミクス分析ツールも提供しており、手動および自動のタンパク質分析機器と、様々な生物学的流体中のタンパク質の定量に使用するイムノアッセイで構成されている。診断薬およびゲノミクス事業では、規制診断薬市場向けのコントロール、キャリブレーター、診断アッセイ、エクソソームベースの分子診断アッセイ、空間ゲノムおよび組織生検分析用の高度な組織ベースのin-situハイブリダイゼーションアッセイ、研究および臨床用途の遺伝学および腫瘍学キットを含む診断薬の開発および製造、遺伝的キャリアスクリーニング、腫瘍学診断、分子コントロール、研究用の製品、および様々な診断用途で使用される血液学、血液化学およびガス、凝固コントロールおよび試薬用の機器およびプロセスコントロール製品の販売を行っている。旧社名はテクネ・コーポレーションで、2014年11月にバイオテクネ・コーポレーションに社名変更した。バイオテクネ・コーポレーションは1976年に法人化され、ミネソタ州ミネアポリスに本社を置いている。もっと見るBio-Techne Corporation 基礎のまとめBio-Techne の収益と売上を時価総額と比較するとどうか。TECH 基礎統計学時価総額US$11.34b収益（TTM）US$181.86m売上高(TTM)US$1.22b62.4xPER（株価収益率9.3xP/SレシオTECH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計TECH 損益計算書（TTM）収益US$1.22b売上原価US$410.16m売上総利益US$804.88mその他の費用US$623.01m収益US$181.86m直近の収益報告Jun 30, 2026次回決算日該当なし一株当たり利益（EPS）1.16グロス・マージン66.24%純利益率14.97%有利子負債／自己資本比率9.5%TECH の長期的なパフォーマンスは？過去の実績と比較を見る配当金0.4%現在の配当利回り27%配当性向TECH 配当は確実ですか？TECH 配当履歴とベンチマークを見るTECH 、いつまでに購入すれば配当金を受け取れますか？Bio-Techne 配当日配当落ち日Aug 24 2026配当支払日Sep 04 2026配当落ちまでの日数1 day配当支払日までの日数12 daysTECH 配当は確実ですか？TECH 配当履歴とベンチマークを見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/23 04:42終値2026/08/21 00:00収益2026/06/30年間収益2026/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bio-Techne Corporation 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。26 アナリスト機関David ToungArgus Research CompanyRobert BambergerBairdRobert WassermanBenchmark Company23 その他のアナリストを表示
Recent Insider Transactions Derivative • Aug 19CEO, President & Director exercised options and sold US$783k worth of stockOn the 15th of August, Kim Kelderman exercised options to acquire 11k shares at no cost and sold these for an average price of US$72.40 per share. This trade did not impact their existing holding. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.
Declared Dividend • Aug 14Fourth quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 17th August 2026 Payment date: 28th August 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 27%. Cash payout ratio: 19%.
お知らせ • Aug 13Bio-Techne Corporation Announces Cash Dividend on Common Shares for the Quarter Ended June 30, 2026, Payable on August 28, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Reported Earnings • Aug 13Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: US$1.17 (up from US$0.47 in FY 2025). Revenue: US$1.22b (flat on FY 2025). Net income: US$181.9m (up 148% from FY 2025). Profit margin: 15% (up from 6.0% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.5%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
ナラティブ更新 • Aug 12TECH: Acquisition Offer And Resilient Pharma Demand Will Support A Balanced OutlookAnalysts have lifted their price target for Bio-Techne from about $61 to roughly $70, citing updated assumptions for revenue growth, profit margins and future P/E. These changes shift their fair value framework higher in spite of a slightly different discount rate outlook.
Recent Insider Transactions Derivative • Jul 31CEO, President & Director exercised options and sold US$702k worth of stockOn the 28th of July, Kim Kelderman exercised 35.00k options at around US$47.60, then sold 29k of the shares acquired at an average of US$72.07 per share and kept the remainder. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$8.9m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions Derivative • Aug 19CEO, President & Director exercised options and sold US$783k worth of stockOn the 15th of August, Kim Kelderman exercised options to acquire 11k shares at no cost and sold these for an average price of US$72.40 per share. This trade did not impact their existing holding. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$11m more than they bought, via options and on-market transactions in the last 12 months.
Declared Dividend • Aug 14Fourth quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 17th August 2026 Payment date: 28th August 2026 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 27%. Cash payout ratio: 19%.
お知らせ • Aug 13Bio-Techne Corporation Announces Cash Dividend on Common Shares for the Quarter Ended June 30, 2026, Payable on August 28, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2026. The quarterly dividend will be payable August 28, 2026, to all common shareholders of record on August 24, 2026. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
Reported Earnings • Aug 13Full year 2026 earnings: EPS misses analyst expectationsFull year 2026 results: EPS: US$1.17 (up from US$0.47 in FY 2025). Revenue: US$1.22b (flat on FY 2025). Net income: US$181.9m (up 148% from FY 2025). Profit margin: 15% (up from 6.0% in FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.5%. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 3% per year, which means it has not declined as severely as earnings.
ナラティブ更新 • Aug 12TECH: Acquisition Offer And Resilient Pharma Demand Will Support A Balanced OutlookAnalysts have lifted their price target for Bio-Techne from about $61 to roughly $70, citing updated assumptions for revenue growth, profit margins and future P/E. These changes shift their fair value framework higher in spite of a slightly different discount rate outlook.
Recent Insider Transactions Derivative • Jul 31CEO, President & Director exercised options and sold US$702k worth of stockOn the 28th of July, Kim Kelderman exercised 35.00k options at around US$47.60, then sold 29k of the shares acquired at an average of US$72.07 per share and kept the remainder. For the year to June 2020, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Kim currently holds less than 1% of total shares outstanding. Company insiders have collectively sold US$8.9m more than they bought, via options and on-market transactions in the last 12 months.
ナラティブ更新 • Jul 29TECH: Merger Premium And Deal Uncertainty Will Restrain Future Earnings AppealAnalysts have nudged their price target for Bio-Techne higher to reflect a shift in fair value from $55.05 to $56.51. This change is supported by updated assumptions for revenue growth, profit margins and future P/E levels, as well as a slightly lower discount rate.
ナラティブ更新 • Jul 15TECH: AI Protein Expansion And Portfolio Rebrand Will Support Balanced Long-Term UpsideAnalysts have reduced their price target on Bio-Techne to $73 from $75, reflecting updated assumptions about the balance between revenue growth expectations, lower projected profit margins, and a slightly higher future P/E multiple. What’s in the News for Bio-Techne Bio-Techne and Merck KGaA agreed to a definitive acquisition deal in which Merck KGaA plans to acquire Bio-Techne for US$73 per share in cash, valuing the company at about US$11.5b and implying an enterprise value of roughly US$11.3b, with the transaction subject to regulatory and shareholder approvals and customary closing conditions.
お知らせ • Jul 08Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein PortfolioBio-Techne Corporation announced the launch of new additions to its R&D Systems AI-Engineered Designer Protein portfolio, designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows. The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions to help researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents. By improving protein performance characteristics such as heat stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery through therapeutic development. These improvements are critical as cell therapies and organoid systems move toward clinical and commercial scale, where minor variations in cell signaling inputs can significantly impact outcomes. These additions build on Bio-Techne's strategy to develop a comprehensive portfolio of next-generation signaling technologies, following an earlier expansion of the R&D Systems AI-Engineered Design Protein portfolio. Together, these innovations, including hyperactive cytokines, heat-stable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled, reproducible systems across the continuum from basic research through process development and scaled-up manufacturing. The newly launched proteins include: FGF-4 Heat Stable – Designed to support pluripotent stem cell maintenance, embryonic development research, and differentiation workflows requiring sustained growth factor activity. FGF-7 Heat Stable – Engineered to support epithelial and tissue regeneration workflows, including advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures. FGF-8b Heat Stable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenic signaling is critical. IL-3 Heat Stable – Designed to support hematopoietic stem and progenitor cell expansion and differentiation across early-stage and lineage-committed cell populations requiring sustained cytokine stability in culture. IL-15 Hyperactive – Engineered to drive increased expansion of NK cells and T cells, supporting cell therapy workflows and immunotherapy research, where enhanced signaling strength and persistence are vital. The expansion of the AI-Engineered Designer Protein portfolio reinforces Bio-Techne's leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing; areas where reproducible scale-up from discovery to production is increasingly a requirement for success.
ナラティブ更新 • Jul 01TECH: Pending Merger Premium Will Constrain Future Earnings AppealBio-Techne's updated analyst price target has been trimmed from about $56.78 to $55.05, as analysts factor in slightly higher assumed revenue growth and P/E levels, along with modestly lower profit margin estimates. What’s in the News for Bio-Techne Merck KGaA agreed to acquire Bio-Techne in an all cash transaction valued between US$11.3b and US$11.5b, which Merck states represents about a 36% premium to Bio-Techne’s trading price at announcement.
ライブニュース • Jun 27Merck KGaA Announces $11.3 Billion Bio-Techne Acquisition Targeting Early 2027 CompletionMerck KGaA has agreed to acquire Bio-Techne in an all-cash transaction valued between $11.3 billion and $11.5 billion, a deal that carries a roughly 36% premium to Bio-Techne’s recent trading price and has been unanimously approved by Bio-Techne’s board, pending regulatory approvals and a shareholder vote. The acquisition is intended to fold Bio-Techne’s protein detection instruments and spatial biology diagnostic technologies into Merck’s broader life science portfolio, with both companies expecting operational synergies and an accretive effect on Merck’s earnings after completion, which is currently targeted for early 2027. Bio-Techne’s share price is around $71.00, with the stock up 47.6% over the past 30 days, reflecting a sharp re-rating ahead of the proposed buyout. The key question for shareholders is how the final transaction terms, timing and regulatory conditions compare with the current market price and whether any deal uncertainty or timeline slippage could affect the risk and return trade-off.
お知らせ • Jun 27Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion.Merck KGaA (XTRA:MRK) entered into a definitive agreement to acquire Bio-Techne Corporation (NasdaqGS:TECH) for $11.5 billion on June 25, 2026. Merck KGaA will acquire Bio-Techne for $73 per share in cash, representing a total enterprise value of approximately $11.3 billion (€9.9 billion). The planned acquisition will be funded through a combination of existing cash on hand and proceeds from new debt. The transaction is subject to approval of merger agreement by target board, approval by regulatory board / committee and approval of offer by target shareholders, subject to satisfaction of customary closing conditions. The proposed transaction has been approved by Bio-Techne's Board of Directors. The transaction is expected to close by late 2026 or early 2027. The proposed transaction is expected to be immediately accretive to EBITDA pre margin of both Life Science and the Group post-closing and EPS pre accretive by year 3 after closing. Cost synergies of approximately $159.6 million (€140 million) are expected to be fully realized by year 3 after closing. Guggenheim Securities, LLC acted as financial advisor for Merck KGaA. J.P. Morgan Securities, Inc. acted as financial advisor for Merck KGaA. Sullivan & Cromwell LLP acted as legal advisor to Merck KGaA. Goldman Sachs & Co. LLC acted as financial advisor for Bio-Techne Corporation. Sidley Austin LLP acted as legal advisor for Bio-Techne Corporation.
Price Target Changed • Jun 26Price target increased by 10% to US$67.69Up from US$61.31, the current price target is an average from 13 analysts. New target price is approximately in line with last closing price of US$71.00. The company is forecast to post earnings per share of US$1.17 for next year compared to US$0.47 last year.
Buy Or Sell Opportunity • Jun 25Now 39% overvalued after recent price riseOver the last 90 days, the stock has risen 39% to US$70.67. The fair value is estimated to be US$50.75, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 2.9% over the last 3 years. Earnings per share has declined by 43%. For the next 3 years, revenue is forecast to grow by 6.5% per annum. Earnings are also forecast to grow by 21% per annum over the same time period.
分析記事 • Jun 18Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn CollaborationBio-Techne (TECH) stock has been in focus after the company partnered with Refeyn on a four hour workflow that links charge heterogeneity, molecular weight, and aggregation in bispecific antibodies and biosimilars at single molecule resolution. See our latest analysis for Bio-Techne. Alongside the Refeyn partnership, Bio-Techne’s recent share price return of 23.79% over 30 days contrasts with a year to date share price decline of 7.80%, while the 1 year total shareholder return of 10.38% sits...
ナラティブ更新 • Jun 17TECH: Portfolio Rebrand And Exosome Exit Will Support Future Margin UpsideAnalysts have trimmed their Bio-Techne price target slightly from $76.00 to $75.00, reflecting updated views on revenue growth, discount rate and profit margin assumptions, while keeping long term P/E expectations broadly similar. What’s in the News for Bio-Techne Bio-Techne reported 3% organic revenue growth in Q4 fiscal 2025 and maintained profitability in what management described as challenging market conditions, according to its Q4 2025 earnings transcript.
ライブニュース • Jun 16Bio-Techne Shares Rise 4% as Activist Investor Urges Review of Company OptionsBio-Techne shares moved higher after Ananym Capital Management disclosed a significant stake in the company. The activist investor is urging Bio-Techne to conduct a broad review of its options, including a possible sale. Ananym argues that exploring a transaction could provide more value to shareholders than the company remaining independent. An activist campaign of this type often puts management under pressure to examine portfolio priorities, capital allocation and potential interest from buyers. This can lead to changes in how Bio-Techne is run or structured. Investors may want to watch for any response from Bio-Techne’s board, including whether it forms a special committee, sets out a formal review process or rejects the call, as each path can carry different execution risks and timelines.
ライブニュース • Jun 06Bio-Techne Unveils Integrated Four-Hour Workflow for Faster Bispecific and Biosimilar AnalysisBio-Techne and Refeyn announced a combined workflow that links charge and size characterization for bispecific antibodies and biosimilars. The workflow connects Bio-Techne’s icIEF fractionation system with Refeyn’s mass photometry platform to correlate charge heterogeneity with molecular weight and aggregation at single-molecule resolution. The integrated process is designed to run in roughly four hours and is aimed at reducing development risk and speeding up biosimilar manufacturing. This collaboration points to a push by Bio-Techne to position its analytical tools more deeply in complex biologics workflows, especially where bispecifics and biosimilars require tighter quality characterization. For investors, the key question is how widely this four-hour workflow will be adopted by biopharma customers and whether it can translate into higher demand for Bio-Techne’s analytical systems and related consumables, given the growing focus on efficiency and risk reduction in biologics development.
ナラティブ更新 • Jun 03TECH: Spatial Biology Platforms And Brand Simplification Will Support A Steady Forward OutlookAnalysts have lowered their price target on Bio-Techne from $75.25 to $61.42, citing updated assumptions that include slightly lower revenue growth, modestly higher profit margins, and a reduced future P/E multiple. What's in the News Bio-Techne stock rallied about 12% over a recent five day period, adding roughly US$780 million in market value to reach around US$7.5b in market capitalization, according to recent coverage.
ナラティブ更新 • May 12TECH: Portfolio Rebrand And Diagnostics Expansion Will Support Stronger Future UpsideAnalysts have adjusted their price target on Bio-Techne to $76.00 from $75.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News Bio-Techne introduced a streamlined brand architecture that groups its offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, to align products with stages of scientific research from discovery through clinical diagnostics (Key Developments).
Recent Insider Transactions Derivative • May 11Executive VP of Finance & CFO exercised options and sold US$517k worth of stockOn the 5th of May, James Hippel exercised 62.00k options at around US$47.60, then sold 57k of the shares acquired at an average of US$9.08 per share and kept the remainder. Since September 2025, James' direct individual holding has increased from 129.88k shares to 153.67k. Company insiders have collectively sold US$9.9m more than they bought, via options and on-market transactions in the last 12 months.
Declared Dividend • May 11Third quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 18th May 2026 Payment date: 29th May 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 46%. Cash payout ratio: 19%.
Price Target Changed • May 07Price target decreased by 11% to US$64.55Down from US$72.27, the current price target is an average from 11 analysts. New target price is 27% above last closing price of US$50.91. Stock is up 2.3% over the past year. The company is forecast to post earnings per share of US$1.20 for next year compared to US$0.47 last year.
お知らせ • May 07Bio-Techne Corporation announces Quarterly dividend, payable on May 29, 2026Bio-Techne Corporation announced Quarterly dividend of USD 0.0800 per share payable on May 29, 2026, ex-date on May 18, 2026 and record date on May 18, 2026.
Reported Earnings • May 06Third quarter 2026 earnings: EPS and revenues miss analyst expectationsThird quarter 2026 results: EPS: US$0.33 (up from US$0.14 in 3Q 2025). Revenue: US$311.4m (down 1.5% from 3Q 2025). Net income: US$51.0m (up 126% from 3Q 2025). Profit margin: 16% (up from 7.1% in 3Q 2025). Revenue missed analyst estimates by 1.5%. Earnings per share (EPS) also missed analyst estimates by 12%. Revenue is forecast to grow 7.0% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions Derivative • Apr 26Executive VP of Finance & CFO exercised options and sold US$3.3m worth of stockOn the 22nd of April, James Hippel exercised options to acquire 56k shares at no cost and sold these for an average price of US$58.58 per share. This trade did not impact their existing holding. Since September 2025, James' direct individual holding has increased from 129.88k shares to 142.72k. Company insiders have collectively sold US$9.2m more than they bought, via options and on-market transactions in the last 12 months.
Buy Or Sell Opportunity • Apr 23Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 23% to US$52.20. The fair value is estimated to be US$71.47, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Earnings per share has declined by 42%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 23% per annum over the same time period.
ナラティブ更新 • Apr 20TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings PotentialAnalysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.
Recent Insider Transactions Derivative • Apr 19CEO, President & Director exercised options and sold US$1.9m worth of stockOn the 14th of April, Kim Kelderman exercised options to acquire 32k shares at no cost and sold these for an average price of US$58.66 per share. This trade did not impact their existing holding. For the year to June 2019, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2025, Kim's direct individual holding has increased from 50.97k shares to 53.08k. Company insiders have collectively sold US$5.9m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Apr 18Bio-Techne Corporation Introduces Streamlined Brand Architecture With Three Portfolio BrandsBio-Techne Corporation announced a streamlined brand architecture designed to enable scientists and clinicians to more easily find the answers they need based on their application and stage of research. The company has organized its products and technologies under three focused portfolio brands -- R&D Systems™, Bio-Techne Spatial™, and Bio-Techne Diagnostics™ -- aligning its solutions with the way modern science progresses from early discovery through translational insights to clinical diagnostics. The portfolio brands will debut at the AACR Annual Meeting 2026 and AAI's IMMUNOLOGY 2026™. The R&D Systems portfolio brings together Bio-Techne's trusted proteins, antibodies, immunoassays, small molecules and innovative instruments used by scientists worldwide. R&D Systems solutions help researchers generate reproducible results, validate discoveries, and advance early-stage research towards clinical application with confidence. R&D Systems provides dependable tools needed to explore, experiment, and uncover new biological insights. R&D Systems also provides key GMP-grade reagents and tools essential for advancing cell and gene therapy workflows. The Bio-Techne Spatial portfolio leverages technologies that help researchers and clinicians translate biology and disease context across both the gold-standard RNAscope™ in situ hybridization technology and the automated COMET™ spatial hyperplex platform. Bio-Techne Spatial solutions enable scalable, high-resolution visualization of RNA and protein with multiomic analysis, delivering exceptional sensitivity and precision to reveal differences in cell structure, identify clinically relevant biomarkers, inform pathology-driven research questions and accelerate therapeutic discovery. The Bio-Techne Diagnostics portfolio provides clinical laboratories and IVD manufacturers with assay kits, IVD-grade reagents, antibodies, molecular controls, calibrators, and proficiency-testing materials needed to design, develop, and validate reliable diagnostic assays. The portfolio supports the full lifecycle of assay development from early design through deployment at scale. By delivering high-quality raw materials and comprehensive assay solutions, Bio-Techne Diagnostics helps ensure accuracy, strengthens clinical decision-making, and ultimately contributes to improved patient outcomes. Together, these three portfolios create a clearer, more connected path for customers by providing a streamlined, end-to-end view of Bio-Techne's solutions, aligning tools and technologies from discovery through translation to clinical diagnostics and accelerating scientific and clinical progress. R&D Systems™ now includes the legacy brands Novus Biologicals™, Tocris Bioscience™, and ProteinSimple™; Bio-Techne Spatial now includes the legacy brands Lunaphore™, and Advanced Cell Diagnostics™; Bio-Techne Diagnostics now includes Asuragen®, Bionostics, Cliniqa, RNA Medical®, and R&D Systems™ Clinical Controls.
ナラティブ更新 • Apr 05TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings MultipleAnalysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).
お知らせ • Mar 25Bio-Techne Corporation Expands Comet Solution Portfolio with Addition of Spyre Focus Panels and Spyre Amplification KitsBio-Techne Corporation announced the expansion of its COMET solution portfolio with the addition of the new SPYRE Focus Panels and SPYRE Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. SPYRE Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE Amplification Kits use seqLA technology to improve the detection of low-abundance and difficult-to-detect targets. Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample.
ナラティブ更新 • Mar 22TECH: Clinical Platform Adoption Will Support Higher Future Earnings MultipleAnalysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).
ナラティブ更新 • Mar 06TECH: Multiomic Platform Expansion Will Support Higher Future Earnings MultipleAnalysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).
Buy Or Sell Opportunity • Feb 20Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 6.5% to US$57.52. The fair value is estimated to be US$72.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.2% over the last 3 years. Earnings per share has declined by 42%. For the next 3 years, revenue is forecast to grow by 6.8% per annum. Earnings are also forecast to grow by 24% per annum over the same time period.
ナラティブ更新 • Feb 20TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward OutlookNarrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.
お知らせ • Feb 16Bio-Techne's Ella Platform Achieves Ce-Ivd Marking Expanding Access to Rapid, Cartridge-Based Immunoassays for European Clinical LaboratoriesBio-Techne Corporation announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex™? assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organizations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.
分析記事 • Feb 12There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) EarningsShareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...
お知らせ • Feb 11Bio-Techne Corporation Announces Executive Changes, Effective March 1, 2026Bio-Techne Corporation announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026. Steve has over two decades of experience as a senior life sciences leader at various companies. As Senior Vice President, Analytical Solutions Division, he is responsible for Bio-Techne's portfolio of protein analysis instruments and immunoassays and has driven strategic initiatives, successfully launched several innovative platforms and delivered strong growth during his four-year tenure. Before joining Bio-Techne, he most recently served as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit. He has an MBA from the Marshall School of Business at the University of Southern California and a M.S. in Biochemistry from Georgetown University.
Price Target Changed • Feb 09Price target increased by 7.5% to US$75.25Up from US$70.00, the current price target is an average from 12 analysts. New target price is 13% above last closing price of US$66.78. Stock is down 4.5% over the past year. The company is forecast to post earnings per share of US$1.26 for next year compared to US$0.47 last year.
Declared Dividend • Feb 06Second quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 13th February 2026 Payment date: 27th February 2026 Dividend yield will be 0.5%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 31%. Cash payout ratio: 22%.
Reported Earnings • Feb 05Second quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2026 results: EPS: US$0.24 (up from US$0.22 in 2Q 2025). Revenue: US$295.9m (flat on 2Q 2025). Net income: US$38.0m (up 8.9% from 2Q 2025). Profit margin: 13% (up from 12% in 2Q 2025). Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) missed analyst estimates by 7.7%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
ナラティブ更新 • Feb 05TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings MultipleAnalysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).
お知らせ • Feb 04Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2025, Payable on February 27, 2026Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2025. The quarterly dividend will be payable February 27, 2026, to all common shareholders of record on February 16, 2026.
お知らせ • Feb 03Bio-Techne Expands 3D Stem Cell and Organoid Culture Portfolio with A Fully Defined Synthetic AlternativeBio-Techne Corporation announced the launch of Cultrex™? Synthetic Hydrogel, a fully defined synthetic extracellular matrix (ECM) designed to support reproducible and scalable 3D stem cell and organoid research. The new product expands Bio-Techne's established Cultrex ECM portfolio, offering researchers a synthetic alternative that reduces lot-to-lot variability while supporting translational and regulatory-aligned research workflows alongside the Company's widely used traditional matrices. Cultrex Synthetic Hydrogel is designed to support the use of 3D organoid models across a wide range of applications, including drug screening, toxicology and personalized medicine, reducing the reliance on animal-component derived matrices and supporting the broader utilization of new approach methodologies (NAMs). By avoiding the biological variability inherent in traditional ECMs, the hydrogel helps researchers standardize experimental conditions across studies and laboratories, enabling more consistent and reliable organoid culture. Cultrex Synthetic Hydogel aligns with the FDA's broader goal of driving innovation to improve translational outcomes by offering a more reliable platform for preclinical research. With the regulatory drive for increased adoption of NAMs across the pharmaceutical industry, researchers increasingly require tools that improve the scalability, consistency, and documentation surrounding organoid workflows. The Cultrex Synthetic HydrogEL launch represents an important step toward the broader adoption of organoid models in support of translational and regulatory- aligned research. Its controlled composition supports consistency and traceability as programs advance toward regulatory-facing studies. This launch further expands Bio-Techne's robust portfolio of solutions for stem cell and organoid culture, including Cultrex Basement Membrane Extracts (BME), as well as recombinant cytokines and growth factors, AI-modified proteins, small molecules, media, and supplements. Together, these offerings provide researchers with the flexibility to select ECM solutions aligned with their experimental, scalability, and regulatory needs.
お知らせ • Jan 28Bio-Techne Launches Simple Plex Ultra- Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological BiomarkersBio-Techne Corporation announced the launch of Simple Plex Ultra-Sensitive Assays on the Ella automated benchtop platform. Early detection of neurodegenerative disease biomarkers has historically been limited by their extremely low abundance in accessible biofluids such as blood. The new, ultrasensitive assays overcome this barrier by delivering step-change improvements on the Ella platform in analytical sensitivity and reliable quantification of key biomarkers, including NFL, GFAP, pTau 217, and Amyloid b (aa1-42). This capability enables researchers to detect subtle, early biological changes that are often missed, accelerating insights into disease onset, progression, and treatment response. The assays build on Ella's proven performance, which is cited in more than 200 peer-reviewed neurology-focused publications and widely adopted in translational and clinical research, driving breakthrough diagnostic and therapeutic advances. Ella's automated workflow reduces manual steps and variability, delivering ultrasensitive assay results with an overall runtime of under three hours. These assays are intended for Research Use Only. This launch strengthens Bio-Techne's immunoassay leadership by combining ultrasensitive proteomic assays with automated instrumentation that improves reproducibility, throughput, and data quality. The Ella platform has been cited in more than 1,000 peer-reviewed publications. Bio-Techne's broad proteomic and spatial biology portfolio continues to drive breakthroughs in neuroscience research and advance precision medicine.
ナラティブ更新 • Jan 22TECH: Multiomic Automation And Buybacks Will Support A Steady Forward OutlookNarrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.
Seeking Alpha • Jan 08Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking Alpha
ナラティブ更新 • Jan 08TECH: Multiomic Partnerships And Automation Will Support A Steady Forward OutlookAnalysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).
ナラティブ更新 • Dec 16TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future OutlookAnalysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).
お知らせ • Dec 09Bio-Techne Launches the Enhanced Leo System Delivering Advanced Multiplexing and High-Throughput Protein AnalysisBio-Techne Corporation announced the expanded launch and first shipment of its next-generation Leo System, powered by Simple Western Technology. The enhanced Leo System introduces dual-channel fluorescence detection alongside chemiluminescence, expanding data throughput and efficiency, and generating greater insights from precious samples. Fluorescence adds a fourth multiplexing option to its molecular weight separation, RePlex, and resampling capabilities to create even more experimental flexibility and tackle complex biological questions. This advance enables researchers to simultaneously quantify targets with distinct expression levels, assess different proteoforms, such as phosphorylated and total protein forms, in the same capillary, multiplex same-weight targets in a single run, and process up to 100 capillaries within three hours.
ナラティブ更新 • Dec 01TECH: Share Buyback Completion And New Partnerships Will Maintain Steady OutlookAnalysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.
ナラティブ更新 • Nov 17TECH: Share Buyback Momentum Will Drive Stronger Performance AheadNarrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).
分析記事 • Nov 08Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts ThinkBio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...
Declared Dividend • Nov 07First quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 17th November 2025 Payment date: 28th November 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 64%. Cash payout ratio: 22%.
Reported Earnings • Nov 06First quarter 2026 earnings: EPS and revenues miss analyst expectationsFirst quarter 2026 results: EPS: US$0.25 (up from US$0.21 in 1Q 2025). Revenue: US$286.6m (down 1.0% from 1Q 2025). Net income: US$38.2m (up 14% from 1Q 2025). Profit margin: 13% (up from 12% in 1Q 2025). Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) also missed analyst estimates by 4.0%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 05Bio-Techne Corporation Declares Dividend for the Quarter Ended September 30, 2025, Payable on November 28, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September 30, 2025. The quarterly dividend will be payable November 28, 2025, to all common shareholders of record on November 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
お知らせ • Nov 04Bio-Techne Corporation and Nucleai Announces the Presentation of Pivotal Data from the SECOMBIT Clinical Trial at the Society for Immunotherapy of Cancer 2025 Annual MeetingBio-Techne Corporation and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting. The study, conducted in collaboration with Professor Paolo Ascierto, Full Professor of Oncology at the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, showcases the significance of spatial biology in translational research by combining, for the first time, an immuno-oncology (IO) multiplex immunofluorescence (mIF) panel with advanced AI-driven multimodal biomarker analysis. Using the COMET platform and a 28-plex mIF panel, researchers profiled 42 pre-treatment biopsies from patients with metastatic melanoma. Nucleai's multimodal spatial operating system integrated high-plex imaging, histopathology, and clinical outcome data to identify distinct immune cell interactions that correlate with progression-free survival (PFS), overall survival (OS), and clinical benefit across three treatment arms incorporating Immune Checkpoint Blockade (ICB). Key Findings: Arm A (MAPKi - ICB): Immune activation markers such as PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells are linked to better outcomes. Arm B (ICB - MAPKi): PD-1+ CD8 T- cells in the tumor invasive margin and their interactions with PD-L1+ CD4 T-cells correlated with improved survival. Arm C (MAPKi - IC B - MAPKi): APC-T-cell interactions in tumor margins associated with better outcomes; macrophage interactions in outer tumor microenvironment (TME) indicated poorer prognosis. The study shows that where immune cells are located and how they interact within the tumor matters significantly for treatment success. By using AI and spatial biology to map these immune niches, researchers can better predict which patients will benefit from specific therapies moving toward more personalized and effective cancer treatment. Availability at SITC 2025 Bio-Techne's full spatial biology portfolio--including the new ProximityScope™? assay and the extended SPYRE™? portfolio will be showcased at Booth #603 at SITC 2025. Visual data from the SECOMBIT study will also be presented in Poster # 528, alongside additional immuno-oncology research from Bio-Techne and its collaborators.
ナラティブ更新 • Nov 03TECH: Product Advances And Index Changes Will Influence Future Demand For Precision ToolsAnalysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.
お知らせ • Oct 28Bio-Techne Launches ProximityScope Assay on the Bond Rx Platform from Leica Biosystems to Advance Spatial Protein-Protein Interactions ResearchBio-Techne Corporation announced the launch of the ProximityScope™ assay, a spatial solution developed for seamless integration with the BOND RX staining platform from Leica Biosystems. This powerful combination enables researchers to visualize functional protein-protein interactions on fixed tissue with subcellular resolution - bringing Leica's automation excellence from Leica Biosystems to the forefront of spatial biology. The ProximityScope assay provides a clear, visual signal only when two proteins of interest are physically close, revealing previously inaccessible insights into biological mechanisms. Designed to work in tandem with the BOND RX stained system from Leica Biosystems, the assay also integrates with ACD's RNAscope Multiomic LS kit, enabling enhanced detection of RNA and protein on the same tissue section. This offers scientists a uniquely powerful tool for both discovery and translational research, sparing precious tissue while delivering novel insights. Traditional methods for studying protein interactions, such as bulk pull-down assays or non-spatial proximity assays, lack localization data or require dissociation cells that lose their spatial orientation. ProximityScope addresses this gap by combining high sensitivity with high specificity and low background, providing unparalleled accuracy and confidence in results. Key applications include visualizing cell-cell interactions for studying immune checkpoints or bispecific antibodies, analyzing cell surface interactions that activate signaling pathways, evaluating antibody-based therapeutics for toxicity and target specificity, and investigating intracellular interactions involved in transcriptional activation.
ナラティブ更新 • Oct 20Chronic Disease Trends And Precision Medicine Will Shape DemandNarrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.
お知らせ • Oct 15Bio-Techne Corporation to Report Q1, 2026 Results on Nov 05, 2025Bio-Techne Corporation announced that they will report Q1, 2026 results at 12:30 PM, US Eastern Standard Time on Nov 05, 2025
お知らせ • Sep 26Bio-Techne Advances Spatial Biology Solutions Bridging Translational Research to Clinical ApplicationsBio-Techne Corporation announced new advancements in its spatial biology portfolio for the RNAscope™? ISH technology and the Lunaphore COMET™?. These solutions help researchers and pathologists bridge the gap between translational research and clinical applications by enabling the detection of RNA and protein biomarkers on the same tissue section. RNAscope™? empowers pathologists and histologists to detect clinically relevant biomarkers--such as viral markers, secreted proteins, point mutations, and chromosomal translocations--within routine anatomic pathology workflows. COMET™? offers fully automated, high-throughput hyperplex analysis of both RNA and protein biomarkers, accelerating spatial multiomic workflows and enabling deeper biological insights. Scientific investigations presented this fall explore the potential of facilitating the diagnostic utility of these technologies. Studies include the use of RNAscope™? for assessing B-cell clonality with IGLL5 detection, and COMET™? for spatial profiling of lymphoid malignancies using a 21-plex seqIF™? panel. These findings demonstrate how spatial biology tools can be integrated into diagnostic workflows, especially in cases with limited tissue availability. Bio-Techne will showcase these innovations at the National Society of Histotechnology (NSH) Convention, taking place September 26-30 in Long Beach, CA. Advanced Cell Diagnostics (ACD) and Lunaphore will exhibit at booths #139 and #427, respectively. Presentations include: RNAscope™? for Routine Anatomic Pathology: Dr. Ryan Bremer will highlight the advantages of RNAscope™? over legacy RNA ISH and other methods for well-known markers and new markers of potential clinical significance, as well as the easy adoption of RNAscope into existing workflows. (Session WS29, Sep. 27, 4:45 p.m.) RNAscope™? of IGLL5 Offers New Insights in B-cell Clonality: Dr. Ishani Das has been selected for a live presentation of her poster focusing on the comparative performance of RNAscope™? for assess B-cell clonality using immunoglobulin kappa and lambda light chain markers, emphasizing the value of concurrent detection of IGLL5 only offered by RNAscope. seqIF™? Panel for Spatial Profiling of Lymphoid Malignancies: Dr. Antonio Sorrentino will present a poster showcasing the COMET technology's potential in improving the diagnosis of lymphoid malignancies, utilizing clinically validated antibodies with a 21-plex (seqIF™?) panel that integrates into the workflow of B-cell lymphomas and conserves valuable tissue from biopsies. Bio-Techne and Leica Biosystems continue to advance their partnership by co-hosting a waterfront reception at Park's Lighthouse on September 28, offering attendees a chance to network and explore RNAscope assays on Leica BOND platforms.
お知らせ • Sep 22+ 1 more updateBio-Techne Corporation, Annual General Meeting, Oct 30, 2025Bio-Techne Corporation, Annual General Meeting, Oct 30, 2025.
ナラティブ更新 • Aug 27Chronic Disease Trends And Precision Medicine Will Shape DemandBio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.
Recent Insider Transactions Derivative • Aug 26Independent Director notifies of intention to sell stockRoeland Nusse intends to sell 17k shares in the next 90 days after lodging an Intent To Sell Form on the 25th of August. If the sale is conducted around the recent share price of US$56.36, it would amount to US$960k. Since September 2024, Roeland's direct individual holding has increased from 43.10k shares to 44.56k. Company insiders have collectively sold US$3.0m more than they bought, via options and on-market transactions in the last 12 months.
Declared Dividend • Aug 08Fourth quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 18th August 2025 Payment date: 29th August 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 38%. Cash payout ratio: 20%.
Reported Earnings • Aug 06Full year 2025 earnings: EPS misses analyst expectationsFull year 2025 results: EPS: US$0.47 (down from US$1.07 in FY 2024). Revenue: US$1.22b (up 5.2% from FY 2024). Net income: US$73.4m (down 56% from FY 2024). Profit margin: 6.0% (down from 14% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 52%. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 06Bio-Techne Corporation Declares Dividend for the Quarter Ended June 30, 2025, Payable on August 29, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended June 30, 2025. The quarterly dividend will be payable August 29, 2025, to all common shareholders of record on August 18, 2025.
Recent Insider Transactions Derivative • Aug 01Executive VP of Finance & CFO exercised options and sold US$2.1m worth of stockOn the 29th of July, James Hippel exercised 168.62k options at around US$44.33, then sold 147k of the shares acquired at an average of US$58.55 per share and kept the remainder. Since September 2024, James' direct individual holding has increased from 99.93k shares to 106.61k. Company insiders have collectively sold US$4.7m more than they bought, via options and on-market transactions in the last 12 months.
Valuation Update With 7 Day Price Move • Jul 28Investor sentiment improves as stock rises 17%After last week's 17% share price gain to US$58.78, the stock trades at a forward P/E ratio of 48x. Average trailing P/E is 40x in the Life Sciences industry in the US. Total loss to shareholders of 38% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at US$61.27 per share.
Major Estimate Revision • May 15Consensus EPS estimates fall by 13%The consensus outlook for fiscal year 2025 has been updated. 2025 EPS estimate fell from US$1.16 to US$1.01 per share. Revenue forecast steady at US$1.22b. Net income forecast to grow 70% next year vs 12% growth forecast for Life Sciences industry in the US. Consensus price target down from US$79.70 to US$70.11. Share price fell 3.1% to US$48.24 over the past week.
お知らせ • May 12Bio-Techne Corporation to Showcase Next-Generation Solutions for Gene and Cell Therapy At American Society of Gene & Cell Therapy 2025Bio-Techne Corporation announced it will showcase its latest spatial biology and cell and gene therapy workflow solutions at the American Society of Gene & Cell Therapy 2025 meeting taking place in New Orleans between May 13th - 17th at the New Orleans Ernest N. Memorial Convention Center. Bio-Techne will feature its cutting-edge advancements for cell and gene therapy development and manufacturing at booth 1537. Highlights include the new RNAscope protease-free workflow for visualization of biodistribution of AAV vectors, transgene mRNA, small RNAs (ASO, siRNA, miRNA) along with functional RNA and protein markers. Bio-Techne's booth will also showcase its solutions to improve cell therapy workflows, including the ProPak GMP cytokines in dose-optimized, single-use bags with weldable tubing for closed-system cell therapy manufacturing, and new AI-modified, designer proteins. The next-generation Simple Western Leo System will also be featured, with this instrument enabling the simultaneous processing of up to 100 samples in a single 3-hour run. Leading researchers along with Maithreyan Srinivasan, PhD, Chief Scientific Officer, Advanced Cell Diagnostics, a Bio-Techne brand, will present the latest innovations with RNAscope technology at ACD's symposium on May 14th at 8:30 am in room 383-385. This session will highlight NextGen RNAscope Multiomics Solutions for Spatial Precision: AAV, small RNA, CAR-T, and Beyond.
Declared Dividend • May 11Third quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 19th May 2025 Payment date: 30th May 2025 Dividend yield will be 0.6%, which is higher than the industry average of 0.4%. Payout Ratios Payout ratio: 38%. Cash payout ratio: 23%.
Price Target Changed • May 09Price target decreased by 11% to US$71.28Down from US$79.70, the current price target is an average from 12 analysts. New target price is 43% above last closing price of US$49.94. Stock is down 38% over the past year. The company is forecast to post earnings per share of US$1.01 for next year compared to US$1.07 last year.
New Risk • May 08New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 22% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (11% net profit margin).
Reported Earnings • May 07Third quarter 2025 earnings: EPS misses analyst expectationsThird quarter 2025 results: EPS: US$0.14 (down from US$0.31 in 3Q 2024). Revenue: US$316.2m (up 4.2% from 3Q 2024). Net income: US$22.6m (down 54% from 3Q 2024). Profit margin: 7.1% (down from 16% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 57%. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 17% per year.
お知らせ • May 07+ 1 more updateBio-Techne Corporation (NasdaqGS:TECH) announces an Equity Buyback for $500 million worth of its shares.Bio-Techne Corporation (NasdaqGS:TECH) announces a share repurchase program. Under the program, the company will repurchase up to $500 million worth of its common. The repurchase program has no expiration date.
お知らせ • Apr 24Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity DetectionBio-Techne Corporation announced an Early Access Program for its latest advancement in spatial biology: a powerful new assay for in situ detection of protein proximity. Built upon Advanced Cell Diagnostics RNAscope technology, this next-generation assay is designed to reveal functional interactions between proteins within intact tissues, delivering a spatial solution to explore how molecular signaling shapes disease processes - offering a truly integrated spatial multiomic view. Conventional methods for studying molecular interactions in tissues that separately measure proteins and RNA risk losing spatial fidelity, while bulk proximity assays provide no localization data. Bio-Techne's proximity detection technology addresses these gaps with a clear visual signal at subcellular resolution, built to be compatible with the RNAscope Multiomic LS workflow on BOND RX. This capability is particularly valuable for research areas where context matters -- such as assessing immune checkpoint dynamics, investigating bispecific antibodies and studying protein interactions at synaptic junctions. The Early Access Program is available to select institutions and researchers interested in incorporating spatial protein proximity capabilities into their workflows. Proof-of-concept data and case studies will be shared at the 2025 American Association for Cancer Research annual meeting, presented by Bio-Techne's scientific team.
お知らせ • Apr 15Bio-Techne Corporation to Report Q3, 2025 Results on May 07, 2025Bio-Techne Corporation announced that they will report Q3, 2025 results on May 07, 2025
お知らせ • Mar 11Bio-Techne Corporation Begins Shipping Leo - A Next Generation High-Throughput Simple Western SystemBio-Techne Corporation announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization. Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run, offering 4x the throughput of the Jess™ Simple Western System and 5x faster turn-around-times than Sally Sue™ and Peggy Sue™ Simple Western Systems. Leo also provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies. Additionally, Leo features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.
お知らせ • Mar 03Bio-Techne Launches New Panel Resolving Hard-To-Decipher Carrier Screening GenesBio-Techne Corporation announced that Asuragen, a Bio-Techne brand, has teamed up with Oxford Nanopore Technologies to launch the AmplideX®? Nanopore Carrier Plus Kit, a new genetic panel and supporting analysis software for carrier screening research. This innovative kit helps laboratories resolve genes that are challenging to analyze by conventional short-read sequencing and only partially resolved by ancillary assays. The panel is available for research use only. In 2021, the American College of Medical Genetics and Genomics (ACMG) updated its recommendations for carrier screening to include many genes that cannot be analyzed by standard short-read sequencing. In fact, half of the 10 most common genes that contribute to the risk of couples having a child with a genetic disorder are problem for short-read sequencing. Until now, laboratories have relied on multiple test technologies, including MLPA, Sanger sequencing, qPCR, long-range PCR, and others, to analyze the recommended genes. The AmplideX Nanopore Carrier Plus Kit addresses two problems for laboratories: it provides a single streamlined method, and it delivers comprehensive sequencing data compared to alternative assays. By combining novel AmplideX long-range PCR and nanopore long reads, it directly captures large genomic variants. The 11-gene panel includes the most prevalent recommended genes that cannot be detected accurately with legacy short-read sequencing methods, allowing labs to replace a patchwork testing approach with a single workflow to simplify sample-to-answer results. The kit also includes software to enable straightforward analysis without the need for advanced bioinformatics resources.
Seeking Alpha • Feb 27Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A BargainSummary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alpha
お知らせ • Feb 20Bio-Techne Corporation Launches Expanded Menu of RNAscope Probes for Human and Mouse Transcriptome to Advance Spatial BiologyBio-Techne Corporation announced the launch of an expanded menu of human and mouse RNAscope™? in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with sensitivity and specificity, the Advanced Cell Diagnostics (ACD) branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species. Representing the most referenced spatial biology technology in the industry, RNAscope provides an unprecedented single-cell view of disease pathology and therapeutic response across a wide range of diseases. Backed by the RNAscope probe guarantee, this new addition to the large and growing RNAscope probe menu enables customers to easily accelerate validation of new RNA biomarkers from single-cell genomics and spatial discovery programs. Available for purchase on bio-techne.com, customers can easily select RNAscope probes together with R&D Systems antibodies to further illuminate changes in cell phenotypes and functional states. With ready-to-use manual and automated formats available for each RNAscope probe, including for use on the automated Lunaphore COMET™? system, researchers can seamlessly advance new RNA and multiomic biomarkers from late discovery to translational research or clinical assay development using the same RNAscope probe design.
お知らせ • Feb 18Bio-Techne Corporation Announces Release of GMP TcBuster Non-Viral Genome Engineering SystemBio-Techne Corporation announced the official release of GMP Transposase mRNA for the TcBuster™? non-viral genome engineering system, supporting the development and manufacture of immune cell- and stem cell-based therapies. The TcBuster System has been widely used by researchers to introduce large cargo genetic modifications in a range of cell types. The new GMP transposase will offer a clearer path to clinic for applications in gene editing cell therapies, such as CAR-T or TCR generation. Non-viral TcBuster offers numerous benefits over traditional lentivirus-based engineering methods for cell therapy development. The natural transposase has been enhanced through protein engineering, resulting in a hyperactive enzyme. As a result, multiple genes can be delivered from a GMP transposon simultaneously while maintaining high editing efficiency and a de-risked insertional profile. By negating the need for viral clearance methods, the TcBuster system also significantly reduces both the time to market and cost requirements for cell therapy developers. Moreover, Bio-Techne has a strong and reliable supply chain for both RUO & GMP grade reagents, including innovative options for closed-system manufacturing, making it a dependable option for scaling from research to clinical and commercial stages. The TcBuster system is compatible with a range of cell types, including immune cells and stem cells, and can be used for a wide range of applications, including autologous CAR-T or TCR manufacturing, allogeneic NK therapies, and for engineering bioprocessing cell lines for therapeutic biologics production.
Declared Dividend • Feb 07Second quarter dividend of US$0.08 announcedDividend of US$0.08 is the same as last year. Ex-date: 14th February 2025 Payment date: 28th February 2025 Dividend yield will be 0.4%, which is about the same as the industry average. Payout Ratios Payout ratio: 32%. Cash payout ratio: 20%.
Reported Earnings • Feb 05Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: EPS: US$0.22 (up from US$0.17 in 2Q 2024). Revenue: US$297.0m (up 9.0% from 2Q 2024). Net income: US$34.9m (up 27% from 2Q 2024). Profit margin: 12% (up from 10% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 4.1%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Life Sciences industry in the US. Over the last 3 years on average, earnings per share has fallen by 14% per year whereas the company’s share price has fallen by 11% per year.
お知らせ • Feb 05Bio-Techne Corporation Declares Dividend for the Quarter Ended December 31, 2024, Payable on February 28, 2025Bio-Techne Corporation announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be payable February 28, 2025, to all common shareholders of record on February 17, 2025. Future cash dividends will be considered by the Board of Directors on a quarterly basis.
お知らせ • Feb 04Bio-Techne Appoints Amy E. Herr to Board of DirectorsBio-Techne Corporation announced the appointment of Amy E. Herr, Ph.D. to serve as an independent director on the Company's Board of Directors beginning on February 1, 2025. Dr. Herr will serve on the Science & Technology Committee of the Board of Directors. Dr. Herr is a Chancellor's Professor of Bioengineering at the University of California, Berkeley. Dr. Herr also currently serves as the Vice President of the Chan Zuckerberg Biohub Network, a group of nonprofit research institutes established to create tools required to understand the mysteries of the cell to ultimately cure, prevent, and manage human disease. Since joining the faculty at UC Berkeley in 2007, Dr. Herr has served in several university, national, and international leadership roles including as the Founding Executive Director of UC Berkeley's Bakar BioEnginuity Hub – an incubator for academic spin-out companies, and on the National Advisory Council for Biomedical Imaging and Bioengineering (NACBIB) for the National Institutes of Health, as well as governmental science advisory boards. Dr. Herr was a co-founder and advisory board member of Zephyrus Biosciences, which was acquired by Bio-Techne in 2016. Dr. Herr holds a Doctor of Philosophy in Mechanical Engineering from Stanford University and a Bachelor of Science in Engineering & Applied Science from Caltech. Dr. Herr's appointment completes a two-year process by the Board of Directors to identify and appoint successors to retiring directors Randy Steer, who retired in 2024, and Dr. Roeland Nusse, who will be retiring later in 2025. Dr. Herr will succeed Dr. Roeland Nusse.
Recent Insider Transactions Derivative • Jan 28CEO, President & Director notifies of intention to sell stockKim Kelderman intends to sell 13k shares in the next 90 days after lodging an Intent To Sell Form on the 27th of January. If the sale is conducted around the recent share price of US$77.05, it would amount to US$1.0m. For the year to June 2018, Kim's total compensation was 11% salary and 89% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since September 2024, Kim's direct individual holding has decreased from 39.94k shares to 39.00k. Company insiders have collectively sold US$4.7m more than they bought, via options and on-market transactions in the last 12 months.
お知らせ • Jan 11Bio-Techne Expands R&D Systems Ai-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative MedicineBio-Techne announced the launch of new designer proteins engineered using advanced Artificial Intelligence (AI) based design platforms and protein evolutionary workflows. This expanded portfolio from Bio-Techne's R&D Systems brand includes IL-2 Heat Stable Agonist, Activin A Hyperactive, FGF basic Heat Stable (available both for research use only (RUO) and made under good manufacturing processes (GMP) for therapeutic development), as well as Wnt/RSPO1 Agonist, Wnt/RSPO2 Agonist, and Wnt/RSPO3 Agonist proteins. These innovative recombinant proteins are designed and engineered to address critical needs in cellular therapy workflows and research applications, including improved cell culture performance and optimized cell expansion. Leveraging generative AI trained on data developed over almost five decades of proteomic leadership, protein library evolution, and rational design, Bio-Techne's expanded portfolio delivers next-generation cytokines and growth factors with tailored functionalities such as hyperactivity, enhanced receptor affinities, and improved heat stability. The new products include: IL-2 Heat StableAgonist: Engineered with enhanced thermal stability and altered receptor affinity for improved biological activity, ideal for cellular therapy applications such as CAR T-cell or Tumor-infiltrating lymphocytes (TIL) expansion. Activin A Hyperactive: Optimized for superior performance in regenerative medicine cell differentiation applications. FGF basic Heat Stable: A robust and versatile growth factor designed for improved protein stability and performance for stem cell culture applications, available in both RUO and GMP formats to support cell therapy manufacturing and advanced research. Wnt/RSPO 1, Wnt/RSPo2, and Wnt/R SPO3 Agonists: Key reagents for advancing stem cell research, organoid development, and regenerative medicine. With this expanded portfolio, Bio-Techne continues to lead the way in delivering disruptive innovations to the life sciences and therapeutic development communities. Bio-Techne designer proteins are available as part of market leading R&D Systems branded portfolio of proteins.
